# A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

> **NCT00627926** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 1095 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **BIOLOGICAL:** Pegylated Interferon Alfa 2a
- **DRUG:** Telaprevir
- **DRUG:** Ribavirin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00627926
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 1095 (ACTUAL)
- **Last updated:** 2014-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00627926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00627926, "A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00627926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*